Webinar & Group Dinner Invite: U.S. Therapeutics 2Q26 Earnings Preview | Monday, 20 July & Thursday, 23 July 2026

Research evidence excerpt

Webinar & Group Dinner Invite: U.S. Therapeutics 2Q26 Earnings Preview | Monday, 20 July & Thursday, 23 July 2026

Discuss the Research

Join Barclays' biotech team for a discussion of 2Q26 earnings, investor positioning, M&A

opportunities, and the most important catalysts ahead. They will highlight their highest-

conviction ideas, underappreciated therapeutic opportunities, and key takeaways from

recent company and KOL engagement.

•• 2Q26 Earnings, Positioning & Key Debates – Where expectations appear misaligned

across biotech and large-cap biopharma, quality-of-earnings debates, and the stocks

best positioned into results (closely watched earnings from BBIO, MDGL, ALNY, PTCT,

INSM, JAZZ, EXEL).

•• M&A and Strategic Optionality – Takeaways from recent deal activity (ABBV-APGE,

VRTX-CRNX, GSK-NUVL), and where strategic interest may emerge next.

•• The Most Important Catalysts into 2H26 – High-impact clinical, regulatory,

commercial, and launch events that could drive meaningful stock performance (incl. P3

readouts from MRK’s TL1A, BMY’s in AF, ADP & IPF, TYRA’s NMIBC data in Aug, MRNA’s

adjuvant melanoma Ph3 readout, KYMR’s Ph2 AD data, IVA’s Ph3 MASH data, MBX’s 12-

week obesity data, CTMX in late line CRC, TRAX in celiac disease, STRO in solid tumors,

ORKA in psoriasis).

•• Highest-Conviction Ideas Across Biotech – The names and therapeutic areas where

our analysts see the greatest disconnect between investor sentiment and long-term

fundamentals.

•• Emerging Therapeutic Opportunities – New perspectives on ATTR-CM (ALNY, BBIO),

MASH (IVA, MDGL), obesity (LLY’s Foundayo launch/Medicare uptake), Alzheimer’s (post

BIIB/IONS CELIA data), rare disease (BBIO, RARE), and other markets.

•• Proprietary Industry Intelligence – Insights from recent company meetings, KOL work,